细胞免疫功能检测在乳腺癌临床分期及预后评估中的应用价值

Value of cellular immune function test in clinical staging and prognosis evaluation of breast cancer

目的探讨细胞免疫功能检测在乳腺癌临床分期及预后评估中的应用价值。方法将2015年7月至2018年8月汕头市中心医院诊治的80例乳腺癌患者作为观察组,选取同期乳腺无异常的80例女性对象作为对照组,比较两组外周血T淋巴细胞亚群免疫功能检测结果。结果观察组各期患者CD3^+均低于对照组,差异均有统计学意义(P均<0.05)。观察组乳腺癌Ⅲ、Ⅳ期患者CD8^+高于Ⅰ、Ⅱ期患者及对照组,差异均有统计学意义(P均<0.05);Ⅲ、Ⅳ期患者CD3^+、CD4^+、CD4^+/CD8^+低于Ⅰ、Ⅱ期患者及对照组,差异均有统计学意义(P均<0.05)。结论细胞免疫功能检测在乳腺癌分期及预后评估中具有较好的应用价值,值得应用推广。

Objective To explore the application value of cellular immune function test in clinical staging and prognosis evaluation of breast cancer. Methods Eighty patients with breast cancer treated from July 2015 to August 2018 in Shantou Central Hospital were selected as observation group, another 80 women without abnormality breast in the same period were selected as control group. The results of T lymphocyte subsets immune function in peripheral blood of the two groups were compared. Results Statistical data showed that CD3^+ in observation group in different stages were all lower than that in control group, and the differences were statistically significant (P all<0.05). CD8^+ in stage Ⅲ and Ⅳ breast cancer patients in observation group was significantly higher than that in stage I and Ⅱ breast cancer patients and control group, and the difference were statistically significant (P all<0.05);CD3^+, CD4^+, CD4^+/CD8^+ in stage Ⅲ and Ⅳ breast cancer patients were lower than that in stage I and Ⅱ breast cancer patients and control group, and the difference were statistilly significant (P all<0.05). Conclusions The detection of cellular immune function has good application value in the staging and prognosis evaluation of breast cancer, and it is worthy of application and promotion.